为什么不是药一刀切?
了解医学的定制方法可以从根本上改变我们如何看治疗的病人。
精密医学
We are pushing the boundaries of personalized treatment to transform how we treat disease.\r\n"}}" id="text-0133090242" class="cmp-text">
我们正在推动个性化治疗的界限将如何治疗疾病。
创建正确的药的病人
Precision medicine has revolutionized how cancer patients are diagnosed and treated. Now, we're taking the principles of precision medicine a step further to fight diseases across immunology, neuroscience and eye care.\r\n"}}" id="text-e5d79c9696" class="cmp-text">
精密医学革命如何诊断和治疗癌症患者。现在,我们正在采取精密医学的原则进一步抗疾病在免疫学、神经科学和眼保健。
工作更聪明的药物给病人更快
At AbbVie, precision medicine is being used across the portfolio to bring medicines to the right patients using advanced technologies and data science to gain unprecedented insights into disease mechanism and patient heterogeneity. Our insights help us to target medicines more precisely, identify opportunities for combinations and provide patients and their physicians with actionable diagnostic tools. We are dedicated to understanding disease and addressing underlying mechanisms in all patients.\r\n"}}" id="text-0bb0556933" class="cmp-text">
AbbVie,精密医学使用整个投资组合带来药物对病人使用先进技术和数据科学获得前所未有的见解和患者的异质性疾病机制。更准确地说,我们的见解帮助我们针对药物识别机会组合和为病人和他们的医生提供可操作的诊断工具。我们致力于理解疾病和解决所有患者的潜在机制。
研究兴趣
\r\nBuilding and using our understanding of biomarkers in solid tumors to guide the development of immunotherapies, targeted small molecule inhibitors and antibody drug conjugates (ADCs).
\r\n
\r\n \r\nContinuing to blaze the trail – impacting patients with hematologic malignancies through mechanistic insights from the clinic that help inform combinations, identification of predictive markers to determine patient segments that respond and development of alternative molecular endpoints to enable faster trials.
\r\n
\r\n \r\nLeveraging novel insights into disease mechanisms from state of the art genomic, genetic and proteomic analyses being conducted in the Genomic Research Center, together with cutting edge data science and analytics.
\r\n
\r\n \r\nDevelopment of companion diagnostics and disease focused panels to help patients and their physicians make data informed treatments decisions.
\r\n
\r\n \r\nDigital pathology – more precision and less tissue. Advanced analytics providing unprecedented insights into disease and predictive markers.
\r\n
\r\n \r\nAchieving this using talent from across the AbbVie organization, from Discovery, GRC, Clinical and Medical Affairs as well as our industry leading datasets comprised of biobanks and our own clinical trial data from multiple disease areas to help us develop the next generation of medicines. \r\n\r\n"}}" id="text-2424536e88" class="cmp-text">
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
- 构建和使用我们的理解在实体肿瘤生物标志物指导免疫疗法的发展,针对小分子抑制剂和抗体药物配合(adc)。狗万正网地址
- 继续开辟道路,影响血液恶性肿瘤患者通过机械的见解从诊所帮助组合,预测标记来确定病人的识别部分替代分子端点的响应和发展加速试验。狗万正网地址
- 利用新颖的见解从最先进的基因疾病机制,遗传和基因组研究中心进行蛋白质组学分析,结合前沿科学和分析数据。
- 狗万正网地址同伴诊断和疾病的发展集中面板来帮助病人和他们的医生使数据治疗决策。
- 数字病理——更精确和更少的组织。高级分析疾病提供前所未有的洞察和预测标记。
- 实现这一使用来自AbbVie组织人才,从发现、GRC、临床和医学事务以及我们的行业领先的数据集组成的生物银行和我们的临床试验数据从多个疾病领域来帮助我们开发新一代的药物。
对快节奏的事业在科学感兴趣吗?
Help us create the future of precision medicine.\r\n"}}" id="text-e5ca6e4745" class="cmp-text">
精密医学的帮助我们创造未来。
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-78da8ad945" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
